Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza
T. R. Abbott, G. Dhamdhere, Y. Liu…·L. S. Qi
This paper develops a CRISPR-Cas13-based strategy called PAC-MAN to inhibit SARS-CoV-2 and influenza A virus in human cells, showing it can degrade viral sequences and reduce replication.